Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

Rifaximin treatment in hepatic encephalopathy.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.

N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.

2.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Epub 2011 Jul 7. Review.

PMID:
21741091
3.
4.

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.

Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP.

Aliment Pharmacol Ther. 2015 Jan;41(1):39-45. doi: 10.1111/apt.12993. Epub 2014 Oct 22.

5.

Durability of rifaximin response in hepatic encephalopathy.

Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N.

J Clin Gastroenterol. 2012 Feb;46(2):168-71. doi: 10.1097/MCG.0b013e318231faae.

PMID:
22011586
6.
7.

RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.

Schulz C, Schütte K, Kropf S, Schmitt FC, Vasapolli R, Kliegis LM, Riegger A, Malfertheiner P.

Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.

8.

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.

Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23.

PMID:
23877348
9.

Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver.

Ali B, Zaidi YA, Alam A, Anjum HS.

J Coll Physicians Surg Pak. 2014 Apr;24(4):269-73. doi: 04.2014/JCPSP.269273.

PMID:
24709242
10.

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP.

Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17.

11.

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1390-7.e2. doi: 10.1016/j.cgh.2013.12.021. Epub 2013 Dec 21.

12.

[Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].

[No authors listed]

MMW Fortschr Med. 2014 Feb 20;156(3):64-5. German. No abstract available.

PMID:
24938070
13.

Rifaximin for the treatment of hepatic encephalopathy.

Mantry PS, Munsaf S.

Transplant Proc. 2010 Dec;42(10):4543-7. doi: 10.1016/j.transproceed.2010.09.173.

PMID:
21168733
14.

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J.

Transplant Proc. 2006 Dec;38(10):3552-5.

PMID:
17175328
15.

Gut flora and hepatic encephalopathy in patients with cirrhosis.

Riordan SM, Williams R.

N Engl J Med. 2010 Mar 25;362(12):1140-2. doi: 10.1056/NEJMe1000850. No abstract available.

PMID:
20335591
16.

Rifaximin treatment in hepatic encephalopathy.

Sharma P, Sharma BC.

N Engl J Med. 2010 Jun 24;362(25):2423-4; author reply 2424-5. No abstract available.

PMID:
20578274
17.

Update on management of patients with overt hepatic encephalopathy.

Chacko KR, Sigal SH.

Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068. Review.

PMID:
23948621
18.

Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).

Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK.

Am J Gastroenterol. 2011 Feb;106(2):307-16. doi: 10.1038/ajg.2010.455. Epub 2010 Dec 14.

PMID:
21157444
19.

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group.

J Hepatol. 2003 Jan;38(1):51-8.

PMID:
12480560
20.

The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.

Huang E, Esrailian E, Spiegel BM.

Aliment Pharmacol Ther. 2007 Oct 15;26(8):1147-61.

Supplemental Content

Support Center